News | January 27, 2023
Sun Pharma launches SEZABY in the US for treatment of neonatal seizures
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The company has been issued ‘Form 483’ with two observations
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
Subscribe To Our Newsletter & Stay Updated
